abs344.txt	purpose		after	failure	of	hypomethylating	agents	(hma)		patients	withmyelodysplastic	syndromes	(mds)	have	dismal	survival	and	no	approved	treatmentoptions	patients	and	methods		we	conducted	a	phase	1b	investigator-initiatedtrial	of	ipilimumab	in	patients	with	higher	risk	mds	who	have	failed	hmas	patients	received	monotherapy	at	two	dose	levels	(dl		3	and	10	mg/kg)	with	aninduction	followed	by	a	maintenance	phase		toxicities	and	responses	wereevaluated	with	ctcae	4	and	iwg-2006	criteria		respectively		we	also	performedimmunologic	assays	and	t-cell	receptor	sequencing	on	serial	samples	results	twenty-nine	patients	from	7	centers	were	enrolled		in	the	initial	dl1	(3	mg)		3of	6	patients	experienced	grade	2-4	immune-related	adverse	events	(irae)	thatwere	reversible	with	drug	discontinuation	and/or	systemic	steroids		in	dl2		4	of5	patients	experienced	grade	2	or	higher	irae		thus		dl1	(3	mg/kg)	was	expandedwith	no	grade	2-4	iraes	reported	in	18	additional	patients		best	responsesincluded	marrow	complete	response	(mcr)	in	one	patient	(3	4%)		prolonged	stabledisease	(psd)	for	≥46	weeks	occurred	in	7	patients	(24%	of	entire	cohort	and	29%of	those	treated	with	3	mg/kg	dose)		including	3	patients	with	more	than	a	yearof	sd		five	patients	underwent	allografting	without	excessive	toxicity		mediansurvival	for	the	group	was	294	days	(95%	ci		240-671+)		patients	who	achieved	psdor	mcr	had	significantly	higher	frequency	of	t	cells	expressing	icos	(induciblet-cell	co-stimulator)	conclusions		our	findings	suggest	that	ipilimumab	dosed	at3	mg/kg	in	patients	with	mds	after	hma	failure	is	safe	but	has	limited	efficacyas	a	monotherapy		increased	frequency	of	icos-expressing	t	cells	might	predictclinical	benefit		clin	cancer	res		24(15)		3519-27		©2018	aacr	
